Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT04338399 is registered in ClinicalTrials.gov with Adlai Nortye Biopharma Co., Ltd. as lead sponsor.

NCT NCT04338399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04338399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 12, 2020
Completion date
November 2, 2025
Enrollment
487 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer